News Releases

Allon product AL-108 successful in Phase Ib clinical trial

VANCOUVER, March 7, 2007— Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that the results of the completed Phase Ib clinical trial of their product AL-108 met all of its objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderl... Continue reading →

Allon files IND for approval of Schizophrenia Phase II clinical trials

VANCOUVER, February 21, 2007— Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that it has filed an Investigational New Drug application (IND) with the United State Food and Drug Administration (FDA) seeking approval to begin human clinical trials evaluating the ... Continue reading →

Allon Therapeutics to present at BIO CEO & Investor Conference in New York

VANCOUVER, February 13, 2007— Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that Gordon McCauley, its President and Chief Executive Officer, will present at the 9th Annual BIO CEO & Investor conference in New York. The presentation is scheduled to take pla... Continue reading →

Allon Therapeutics confirms milestones for 2007 and makes further scientific progress

VANCOUVER, January 31, 2007— Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today the Company’s key milestones for 2007 that include the completion of two ongoing Phase II human efficacy trials and the initiation of the recently announced Phase II human efficacy tria... Continue reading →

Michael J. Fox Foundation funds Allon to evaluate AL-108 for Parkinson's disease

VANCOUVER, January 24, 2007— Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced it has received funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to evaluate the effectiveness of Allon’s lead drug AL-108 in pre-clinical models of Parkinson’... Continue reading →

← Older posts Newer posts →